Multiple sources report that the White House has signed off on a plan to remove Dr. Marty Makary as FDA commissioner, though the decision may not be final due to President Trump’s history of reversing staffing choices. Makary, confirmed in March 2025 and aligned with Health Secretary Robert F. Kennedy Jr., has faced criticism over delayed reviews of the abortion pill mifepristone, rejections of rare-disease drug applications, and internal agency instability marked by staff departures. The FDA has also faced pressure over vaping regulations, particularly flavored e-cigarettes, and broader scrutiny from industry, antiabortion groups, and former officials. While some sources indicate Trump has approved Makary’s removal, others describe it as under consideration. The Wall Street Journal first reported the plan, and the White House has not directly commented, issuing only a general statement praising the administration’s performance.

The headline and summary are AI-generated to reduce bias